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SUMMARY Hailey-Hailey disease is a rare autosomal dominant skin 
disorder that typically affects the intertriginous areas. The responsible defect 
has been identified in the gene named ATP2C1 on chromosome 3q21-24. 
We present a 50-year-old man with a 16-year history of blistering eruptions 
and positive familial history where this disease had appeared through four 
generations. The diagnosis was confirmed by histopathologic studies and 
negative immunofluorescence findings. A combination of topical tacrolimus 
therapy and oral erythromycin seemed to play a considerable part in this 
case, in which all of the lesions healed within 2 weeks. 
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 INTRODUCTION
 Hailey-Hailey disease is an autosomal domi-
nant skin disorder that typically affects the inter-
triginous areas. The primary lesion is a flaccid 
vesicle or bulla on erythematous or normal skin, 
which ruptures easily and forms macerated ero-
sions with crusting and scaling. Development of 
chronic vegetations and painful fissures is com-
mon, and it occurs without scarring, leaving post-
inflammatory hyperpigmentations. The eruption 
runs a chronic course, and the lesions tend to wax 
and wane. Histopathologically, the classic findings 
in a fully developed lesion of Hailey-Hailey disease 
include the so-called dilapidated brick wall in which 
acantholysis occurs throughout the full thickness 
of the epidermis. The histopathologic findings in 
an early, unruptured vesicular lesion of Hailey-Hai-
ley disease include incipient acantholysis marked 
by vacuoles around keratinocytes confined to the 
lower portion of the epidermis, which can be dif-
ficult to distinguish from pemphigus vulgaris.
 We present a patient with disseminated Hailey-
Hailey disease and therapeutic efficacy of 0.1% 
tacrolimus ointment combined with erythromycin 
per os.
CASE REPORT
 A 50-year-old man with a 16-year history of flex-
ural blistering eruptions presented with vesicles, 
erosions and erythema in the intertriginous areas 
and with multiple truncal lesions. Erythematous 
and livid lesions with odorous vegetations were 
found in the groin and genital region (Fig. 1a, b). 
Oral mucosa, larynx, esophagus and conjunctivae 
were not affected. His medical history included ad-
iposity (140 kg) and arterial hypertension. His fa-
ther, his oldest sister, her daughter and her niece 
had similar lesions (Fig. 2). They all were treated 
at our Department, where the disease was con-
firmed. Initial lesions in intertriginous areas were 
also found in his fraternal twin sister. Biopsy spec-
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imens showed intraepidermal clefts of a varying 
size both suprabasally and higher in the epidermis 
as well as the characteristic incomplete acantholy-
sis in large parts of the epidermis (Figs. 3 and 4). 
Results of direct and indirect immunofluorescence 
evaluation were negative. 
In the initial phase of the disease, local cortico-
steroid therapy (betamethasone ointment) leads 
to complete regression; however, it is ineffective 
in disseminated forms of the disease. During the 
patient’s first hospitalization at our Department, 
the local retinoid therapy applied did not result in 
healing. Systemic retinoid therapy with local cor-
ticosteroid applied intermittently reduced the dis-
ease activity. The initial dose of retinoid was 50 
mg per day, gradually lowered down to 25 mg over 
2 months and prolonged with 25 mg for one year 
more. Upon the disease relapse, the patient ap-
plied local corticosteroid therapy, which produced 
local side effects of skin atrophy and striae. Two 
years before, he experienced the last rapid exac-
erbation of the disease after exposure to UV radia-
tion during summer. Then, during his last hospital 
stay, oral treatment with erythromycin, 2x500 mg 
daily and 0.1% tacrolimus ointment resulted in 
healing of the erosions in 2 weeks, with post-in-
flammatory hyperpigmentations (Fig. 5a, b). Local 
therapy with tacrolimus ointment was prolonged 
for the next 2 months. When tacrolimus ointment 
therapy was interrupted, there was a recurrence of 
vesiculobullous lesions.
DISCUSSION
 Hailey-Hailey disease, or familial benign chron-
ic pemphigus, is a rare autosomal dominant condi-
tion that involves recurrent blistering of the skin (1-
4). The pathomorphology of Hailey-Hailey disease 
originates in the epidermis of the skin, where there 
is suprabasal keratinocyte acantholysis usually in-
volving all layers of the epidermis. This acantholy-
sis results in a dilapidated brick wall appearance. 
a)
Figure 1a) and b). Lesions on the trunck and in 
the genital region
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Figure 2. Pedigree: solid symbols, individuals af-
fected by Hailey-Hailey disease (II-6 our patient, 
I-1 his father, II-1 his oldest sister, III-1 her daugh-
ter, IV-2 her grand-daughter, and II-8 his fraternal 
twin sister).
Figure 3. Intraepidermal clefts and incomplete ac-
antholysis
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At the molecular level, the manifestation of Hailey-
Hailey disease has been attributed to the genetic 
defect of the ATP2C1 gene involving a calcium 
pump driven by adenosine triphosphate, resulting 
in altered levels of cytosolic calcium (3,4). What 
provokes the breakdown of the desmosome-kera-
tin tonofilament complex resulting in acantholytic 
keratinocytes remains unknown and this may ex-
plain difficulties in the treatment of the disease, 
often resulting in relapses. A variety of therapeutic 
modalities have been recommended for the treat-
ment of Hailey-Hailey disease. Although none of 
these regimens provides “cure”, they can sup-
press flare-ups. Recommendations range from 
antibiotics to control secondary bacterial infec-
tions through immunomodulating therapy with sys-
temic and topical corticosteroids (5), cyclosporine 
(13,14), retinoid (15), and topical vitamin D (16). 
Other methods include photodynamic therapy with 
5-aminolevulinic acid (17), dermabrasion (18), 
carbon dioxide laser therapy (19,20), and surgi-
cal excision (21). A common approach to the treat-
ment of Hailey-Hailey disease is the use of topical 
steroids. The greatest benefit has been observed 
when topical corticosteroids are used promptly 
during the initial phases of eruptions. Due to long-
term use and local side effects such as folliculitis, 
skin atrophy, striae and telangiectases, we wanted 
to apply steroid-free therapy during the patient’s 
last hospitalization. Because of the disseminated 
distribution of the lesions, surgical methods and 
carbon dioxide laser treatment were not consid-
ered as an appropriate therapeutic option. The 
immunosuppressive agent cyclosporine has been 
proven to be effective in the treatment of Hailey-
Hailey disease pemphigoid lesions. The problem 
with potential long-term cyclosporine utilization, 
however, lies in the risk of developing hyperten-
sion and nephrotoxicity. Due to disseminated le-
sions, local side effects of corticosteroid therapy 
and patient’s persistent hypertension, we decided 
to treat our patient with another immunosuppre-
sant, tacrolimus ointment, in combination with 
oral erythromycin. Tacrolimus, like cyclosporine, 
targets a calcium-activated phosphatase called 
calcineurin, that in turn reduces the activity of T-
lymphocytes and blocks the expression of several 
cytokines (interleukins IL-2, IL-3, IL-4, IL-5, granu-
locyte-monocyte colony-stimulating factor, and tu-
Figure 4. Intraepidermal clefts and incomplete ac-
antholysis
Figure 5a) and 5b).  Lesions on the trunk and in the genital region after 2 weeks of therapy
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mor necrosis factor α) resulting in inflammation, 
redness and itching. In addition, tacrolimus may 
also have direct effects on skin cells (keratino-
cytes). It appears to reduce the number of IL-8 
cytokine receptors on the keratinocytes, hence 
reducing inflammation (22). It is suggested that 
the mechanism of action of topically applied tacro-
limus ointment in Hailey-Hailey disease must be 
related in some way to the immunomodulating ef-
fect of the compound. We chose erythromycin be-
cause of its efficacy in another blistering disease 
(23,24). There are reports on its successful use in 
both children and adults for bullous pemphigoid. 
In addition, erythromycin is a safe treatment with 
no requirement for blood monitoring. The exact 
mechanism of action of erythromycin in bullous 
disorders is unknown but it is thought to be due 
to its anti-inflammatory action rather than antimi-
crobial effects. Erythromycin has been observed 
to inhibit neutrophil chemotaxis in vivo, and also 
has steroid-sparing properties. We started with 
systemic erythromycin therapy, 2x500 mg daily 
for 2 weeks, in combination with tacrolimus oint-
ment. Local therapy with tacrolimus ointment was 
prolonged for the next 2 months as maintenance 
therapy. During therapy with tacrolimus we could 
not detect any symptoms or signs of systemic tox-
icity. When tacrolimus ointment therapy was inter-
rupted there was a recurrence of vesiculobullous 
lesions. 
CONCLUSION
 We find it very interesting and valuable to pres-
ent this rare hereditary disease which in our case 
had appeared through four generations. We could 
observe the impact of triggers (adiposity, sweating, 
UV radiation, secondary bacterial infections) on 
the disease exacerbation. In this case, the bullous 
lesions responded dramatically to topical tacrolim-
us ointment in combination with oral erythromycin. 
Considering that the reported cases of Hailey-Hai-
ley disease which responded to topical tacrolimus 
ointment needed one month for resolution of the 
lesions (25,26), the combination of topical tacroli-
mus and oral erythromycin therapy seemed to play 
a considerable part in this disease, as the lesions 
healed within 2 weeks of treatment. In conclusion, 
we propose this combination therapy in patients 
with disseminated distribution of the lesions, and 
especially topical tacrolimus as steroid-free thera-
py also suitable for maintenance therapy. 
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